Advancing Postmenopausal Preventive Therapy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 385 participants.

Also called NCT04103476

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 385 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04103476
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04103476. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-13 (actual); primary completion 2026-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Advancing Postmenopausal Preventive Therapy
Acronym
APPT
Condition
Atherosclerosis
Condition
Cognitive Decline
Intervention (Combination product)
Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
Intervention (Other)
Placebo
Lead sponsor
University of Southern California (class: other)
Collaborator
National Institute on Aging (NIA) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct04103476
Content hash
284345e10bceb8bda03c806559f5386a423e4eac7ca014b086bb24728d13d08e